Inflammatory breast cancer (IBC) and patterns of recurrence - Understanding the biology of a unique disease
Inflammatory breast cancer (IBC) and patterns of recurrence - Understanding the biology of a unique disease
复制标题
DOI：
10.1002/cncr.22927
复制
发表时间：
2007-10-01
期刊：
影响因子：
6.2
通讯作者：
Hortobagyi, Gabriel N.
中科院分区：
文献类型：
--
作者：
Cristofanilli, Massimo;Valero, Vicente;Hortobagyi, Gabriel N.
背景。炎性乳腺癌（IBC）是原发性乳腺癌最具侵袭性的表现。作者比较了 IBC 和非 IBC 局部晚期乳腺癌 (LABC) 的预后特征，以深入了解该疾病实体的生物学。这项回顾性分析由 1071 名患者组成，其中 240 名 IBC 患者和 831 名非 IBC LABC 患者参加了 10 项连续临床试验（每个疾病组 5 名）。所有患者均接受类似的多学科治疗。作者测量了每个部位从治疗开始到疾病复发或最后一次随访日期（无复发生存期）的疾病复发时间以及到最后一次随访或死亡日期的总生存率。 结果。中位随访期为 69 个月（范围：1-367 个月）。 IBC 组和非 IBC LABC 组的病理完全缓解率分别为 13.9% 和 11.7% (P = .42)。 IBC 和非 IBC LABC 的 5 年累积复发率估计分别为 64.8% 和 43.4% (P < .0001)。 IBC 的局部复发和远处软组织和骨疾病的累积发生率显着较高。 IBC 组的 5 年总生存 (OS) 率为 40.5%（95% CI，34.5%-47.4%），非 IBC LABC 组为 63.2%（95% CI，60.0%-66.6%；P < .0001）。结论。与 LABC 相比，EBC 与更差的预后和独特的早期复发模式相关。这些数据表明，研究影响癌细胞“归巢”的因素可能为 IBC 提供新的治疗策略。
BACKGROUND. Inflammatory breast cancer (IBC) is the most aggressive manifestation of primary breast cancer. The authors compared the prognostic features of IBC and non-IBC locally advanced breast cancer (LABC) to gain insight into the biology of this disease entity.METHODS. This retrospective analysis consisted of 1071 patients, comprising 240 patients with IBC and 831 patients with non-IBC LABC who were enrolled in 10 consecutive clinical trials (5 from each disease group). All patients received similar multidisciplinary treatment. The authors measured time to disease recurrence for each individual site from the start of treatment to the date of disease recurrence or last follow-up (recurrence-free survival) and overall survival rates to the date of last follow-up or death.RESULTS. The median follow-up period was 69 months (range, 1-367 months). Pathologically complete response rates were 13.9% and 11.7% in the IBC and non-IBC LABC groups, respectively (P = .42). The 5-year estimates of cumulative incidence of recurrence were 64.8 % and 43.4% (P < .0001), respectively, for IBC and non-IBC LABC. IBC had significantly higher cumulative incidence of locoregional recurrence and distant soft-tissue and bone disease. The 5-year overall survival (OS) rate was 40.5% for the IBC group (95% CI, 34.5%-47.4%) and 63.2% for the non-IBC LABC group (95% CI, 60.0%-66.6%; P < .0001).CONCLUSIONS. EBC was associated with a worse prognosis and a distinctive pattern of early recurrence compared with LABC. These data suggested that investigating factors affecting "homing" of cancer cells may provide novel treatment strategies for IBC.